FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

SPOTLIGHT: FDA approves Wyeth's Torisel

May 30, 2007 — 8:01pm ET

Free newsletter via e-mail
Tools


The FDA has approved Wyeth's Torisel for advanced renal cell carcinoma. In Phase III, Torisel improved median overall survival by 49 percent compared to interferon-alpha. Release

Click here to get the FierceBiotech email newsletter for FREE!


Be the first to comment

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.